MCID: TRN015
MIFTS: 56

Transient Cerebral Ischemia

Categories: Cardiovascular diseases

Aliases & Classifications for Transient Cerebral Ischemia

MalaCards integrated aliases for Transient Cerebral Ischemia:

Name: Transient Cerebral Ischemia 12 55 15 73
Transient Ischemic Attack 12 54 55 6 43 73
Tia - Transient Ischaemic Attack 12
Transient Cerebral Ischaemia 12
Transient Ischemic Attacks 12
Ischemic Attack, Transient 44
Tia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:224
ICD10 33 G45.9
ICD9CM 35 435.8
MeSH 44 D002546
NCIt 50 C50781

Summaries for Transient Cerebral Ischemia

MedlinePlus : 43 A transient ischemic attack (TIA) is a stroke that lasts only a few minutes. It happens when the blood supply to part of the brain is briefly blocked. Symptoms of a TIA are like other stroke symptoms, but do not last as long. They happen suddenly, and include Numbness or weakness, especially on one side of the body Confusion or trouble speaking or understanding speech Trouble seeing in one or both eyes Difficulty walking Dizziness Loss of balance or coordination Most symptoms of a TIA disappear within an hour, although they may last for up to 24 hours. Because you cannot tell if these symptoms are from a TIA or a stroke, you should go to the hospital right away. TIAs are often a warning sign for future strokes. Taking medicine, such as blood thinners, may reduce your risk of a stroke. Your doctor might also recommend surgery. You can also help lower your risk by having a healthy lifestyle. This includes not smoking, not drinking too much, eating a healthy diet, and exercising. It is also important to control other health problems, such as high blood pressure and cholesterol. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Transient Cerebral Ischemia, also known as transient ischemic attack, is related to ischemia and stroke, ischemic, and has symptoms including angina pectoris, back pain and chest pain. An important gene associated with Transient Cerebral Ischemia is NOTCH3 (Notch 3), and among its related pathways/superpathways are Folate Metabolism and IL-17 Family Signaling Pathways. The drugs Aspirin and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and eye.

NINDS : 54 A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Wikipedia : 76 A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by loss of blood... more...

Related Diseases for Transient Cerebral Ischemia

Diseases related to Transient Cerebral Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
# Related Disease Score Top Affiliating Genes
1 ischemia 30.6 CASP3 HSPA1A HSPA4 MAP2
2 stroke, ischemic 26.7 APOH CASP3 HSPA4 MAP2 NOTCH3
3 mini stroke 11.6
4 moyamoya disease 1 11.4
5 cerebritis 11.1
6 neuronitis 10.7
7 purulent labyrinthitis 10.3 CCL2 IL1B
8 aging 10.2
9 retinitis pigmentosa 73 10.2 CCL2 IL1B
10 internal hemorrhoid 10.1 CASP3 HSPA4
11 trypanosomiasis 10.1 CCL2 IL1B ODC1
12 endotheliitis 10.1
13 cerebral artery occlusion 10.0 IL1B ODC1
14 erdheim-chester disease 10.0 CCL2 IL1B
15 hyperglycemia 10.0
16 occlusion precerebral artery 10.0 CASP3 HSPA1A MAP2
17 brain injury 9.9
18 hypoxia 9.9
19 central nervous system disease 9.8 CASP3 IL1B NOTCH3
20 alzheimer disease 9.7
21 diabetes mellitus, noninsulin-dependent 9.7
22 orthostatic intolerance 9.7
23 anxiety 9.7
24 middle cerebral artery infarction 9.7
25 cardiac arrest 9.7
26 chlamydia 9.7
27 transient global amnesia 9.7
28 patent foramen ovale 9.7
29 hypothyroidism 9.7
30 vascular disease 9.7
31 dermoid cyst 9.7
32 cockayne syndrome 9.7
33 pneumonia 9.7
34 adenoma 9.7
35 thyroiditis 9.7
36 amaurosis fugax 9.7
37 depression 9.7
38 aneurysm 9.7
39 headache 9.7
40 atrial septal aneurysm 9.7
41 toxic encephalopathy 9.6 CASP3 GRIN2A IL1B MAP2
42 carotid artery occlusion 9.3 APOH HSPA1A MAP2
43 malaria 9.1 CASP3 CCL2 HSPA4 IL1B ODC1

Comorbidity relations with Transient Cerebral Ischemia via Phenotypic Disease Network (PDN): (show top 50) (show all 89)


Active Peptic Ulcer Disease Acute Cystitis
Acute Myocardial Infarction Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Atrioventricular Block
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Maxillary Sinusitis Chronic Myocardial Ischemia
Communicating Hydrocephalus Conjunctivitis
Conversion Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Facial Paralysis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Inner Ear Disease
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Ischemic Heart Disease Kidney Disease
Labyrinthitis Left Bundle Branch Hemiblock

Graphical network of the top 20 diseases related to Transient Cerebral Ischemia:



Diseases related to Transient Cerebral Ischemia

Symptoms & Phenotypes for Transient Cerebral Ischemia

UMLS symptoms related to Transient Cerebral Ischemia:


angina pectoris, back pain, chest pain, edema, headache, pain, sciatica, seizures, syncope, tremor, amaurosis fugax, transient ischemic attacks, differing symptoms, transient ischemic attacks, stereotypic symptoms, chronic pain, vertigo/dizziness, sleeplessness

Drugs & Therapeutics for Transient Cerebral Ischemia

Drugs for Transient Cerebral Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 404)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-78-2 2244
2
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
3
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55142-85-3 5472
4
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
5
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
6
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 137862-53-4 60846
7
Amlodipine Approved Phase 4,Phase 3,Not Applicable 88150-42-9 2162
8
Losartan Approved Phase 4 114798-26-4 3961
9
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 9908 54680692
10
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable 1951-25-3 2157
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
12
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
13
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 6691 54678486
14
Dobutamine Approved Phase 4,Phase 3 34368-04-2 36811
15
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
16
Cilostazol Approved, Investigational Phase 4,Phase 3,Not Applicable 73963-72-1 2754
17
Dalteparin Approved Phase 4,Phase 3,Phase 2 9005-49-6
18
Enoxaparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6 772
19
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772 46507594
20
Tranexamic Acid Approved Phase 4,Not Applicable 1197-18-8 5526
21
Candesartan cilexetil Approved Phase 4,Phase 3 145040-37-5 2540
22
Ticagrelor Approved Phase 4,Phase 3,Phase 2 274693-27-5 9871419
23 Edoxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 480449-70-5
24
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
25
Dipyridamole Approved Phase 4,Phase 3,Not Applicable 58-32-2 3108
26
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
27
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
28
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
29
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable 657-24-9 14219 4091
30
Everolimus Approved Phase 4,Phase 3,Not Applicable 159351-69-6 6442177
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Not Applicable 22916-47-8 4189
32
Sirolimus Approved, Investigational Phase 4,Phase 3,Not Applicable 53123-88-9 5284616 6436030 46835353
33
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
34
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
35
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
36
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
37
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
38
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
39
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
40
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
41
Pravastatin Approved Phase 4,Phase 3,Not Applicable 81093-37-0 54687
42
Acenocoumarol Approved, Investigational Phase 4,Phase 3 152-72-7 9052 54676537
43
Apixaban Approved Phase 4,Phase 3,Not Applicable 503612-47-3 10182969
44
Adenosine Approved, Investigational Phase 4 58-61-7 60961
45
Allopurinol Approved Phase 4 315-30-0 2094
46
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
47
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
48
Fluvastatin Approved Phase 4 93957-54-1 1548972
49
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
50
Febuxostat Approved Phase 4,Not Applicable 144060-53-7 134018

Interventional clinical trials:

(show top 50) (show all 667)
# Name Status NCT ID Phase Drugs
1 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
2 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
3 ASCEND: A Study of Cardiovascular Events iN Diabetes Unknown status NCT00135226 Phase 4 aspirin;Omega-3-acid Ethyl Esters;Placebo Aspirin;Placebo omega-3-Ethyl Esters
4 Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Unknown status NCT02594800 Phase 4 Rosuvastatin
5 Preventive Effects of Ginseng Against Atherosclerosis Unknown status NCT02796664 Phase 4
6 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
7 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
8 The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion Unknown status NCT02594995 Phase 4 NBP
9 Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
10 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
11 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
12 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4 Aspirin
13 Hypertension Control Based on Home Blood Pressure Unknown status NCT00198562 Phase 4 Amlodipine, Losartan
14 Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Unknown status NCT02256683 Phase 4 Dabigatran etexilate;Phenprocoumon
15 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
16 Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack Completed NCT00931788 Phase 4 Antihypertensive agents and lipid lowering therapy
17 Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke Completed NCT00147602 Phase 4 atorvastatin
18 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke Completed NCT00924638 Phase 4
19 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
20 Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease Completed NCT00962988 Phase 4 Cost-Free Pharmacotherapy Group
21 Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial Completed NCT01559298 Phase 4 Aspirin (80 mg/d) + clopidogrel (75 mg/d);Aspirin
22 EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA Completed NCT00562588 Phase 4 Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg);ASA 100 mg qd
23 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) Completed NCT02348723 Phase 4 Warfarin;Dabigatran Etexilate 150mg
24 Metformin-Dipyridamole Interaction Trial Completed NCT01613755 Phase 4 Metformin, dipyridamole;Metformin
25 Safety and Efficacy Study Comparing 3 New Types of Coronary Stents Completed NCT01166685 Phase 4
26 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery Completed NCT01334866 Phase 4
27 A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease Completed NCT00074984 Phase 4
28 PreFER Managed Ventricular Pacing (MVP) For Elective Replacement Completed NCT00293241 Phase 4
29 The Effects of Levosimendan During Mitral Valve Surgery Completed NCT01969071 Phase 4 Levosimendan;Dobutamine
30 Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During and After Carotid Artery Stenting (CAS) in Asymptomatic Patients Prior to Cardiac Surgery Completed NCT01146301 Phase 4 Clopidogrel
31 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) Completed NCT00234065 Phase 4 Cilostazol;Aspirin
32 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4 Valsartan;Non-ARB
33 Carvedilol Post-intervention Long-term Administration in Large-scale Trial Completed NCT01155635 Phase 4 Carvedilol;No Carvedilol
34 Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis Completed NCT00257283 Phase 4 Omega-3-acid ethyl esters 90
35 Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II) Completed NCT00289042 Phase 4 Enoxaparin
36 MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure Completed NCT00262119 Phase 4
37 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed NCT00134160 Phase 4 Olmesartan medoxomil;Calcium channel blockers (amlodipine, azelnidipine)
38 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
39 Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial Completed NCT01035450 Phase 4
40 Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan Completed NCT01069302 Phase 4 Clopidogrel;Clopidogrel;Clopidogrel;Clopidogrel
41 Tranexamic Acid Dosing for Total Joint Arthroplasty Completed NCT02584725 Phase 4 Tranexamic Acid
42 Study of Heart and Renal Protection Completed NCT00125593 Phase 4 Simvastatin 20 mg;Ezetimibe 10mg;Placebo
43 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
44 NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial Completed NCT01303640 Phase 4
45 Short and Optimal Duration of Dual Antiplatelet Therapy Study Completed NCT01659034 Phase 4 Thienopyridine for 3 months
46 Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack Recruiting NCT02122718 Phase 4 Allopurinol;Placebo
47 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Recruiting NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
48 Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure Recruiting NCT03445949 Phase 4 short postimplantation dual antiplatelet therapy;extended postimplantation dual antiplatelet therapy
49 Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives Recruiting NCT01563731 Phase 4 all approved antihypertensive drugs; all approved statins
50 Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD Recruiting NCT03417388 Phase 4 High dose potent statin;PCSK9 Inhibitor;ACE-I (lisinopril) or ARB (losartan);Aspirin

Search NIH Clinical Center for Transient Cerebral Ischemia

Cochrane evidence based reviews: ischemic attack, transient

Genetic Tests for Transient Cerebral Ischemia

Anatomical Context for Transient Cerebral Ischemia

MalaCards organs/tissues related to Transient Cerebral Ischemia:

41
Brain, Heart, Eye, Testes, Spinal Cord, Retina, Kidney

Publications for Transient Cerebral Ischemia

Articles related to Transient Cerebral Ischemia:

(show top 50) (show all 649)
# Title Authors Year
1
Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). ( 29084736 )
2018
2
Ischemic stroke/transient ischemic attack events and carotid artery disease in the absence of or with minimal coronary artery calcification: Results from the Multi-Ethnic Study of Atherosclerosis. ( 29852401 )
2018
3
A Modified Definition for Obstructive Sleep Apnea in Home Sleep Apnea Testing after Stroke or Transient Ischemic Attack. ( 29428326 )
2018
4
Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. ( 29880551 )
2018
5
Genistein attenuates brain damage induced by transient cerebral ischemia through up-regulation of Nrf2 expression in ovariectomized rats. ( 29688134 )
2018
6
Effects of Scrambling trumpet Creeper flavone on transient cerebral ischemia model (TIA) in rats. ( 29686511 )
2018
7
Upregulation of heme oxygenase-1 protected against brain damage induced by transient cerebral ischemia-reperfusion injury in rats. ( 29805479 )
2018
8
Neuroprotection of ulinastatin on transient cerebral ischemia via antioxidative mechanisms. ( 29685007 )
2018
9
Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis. ( 29335335 )
2018
10
EAAC1 gene deletion reduces adult hippocampal neurogenesis after transient cerebral ischemia. ( 29720605 )
2018
11
Correction to: Inactivation of NSF ATPase Leads to Cathepsin B Release After Transient Cerebral Ischemia. ( 29796935 )
2018
12
Transient ischemic attack characterized by external strabismus of the left eye: A case report. ( 29901646 )
2018
13
TOPK Promotes Microglia/Macrophage Polarization towards M2 Phenotype via Inhibition of HDAC1 and HDAC2 Activity after Transient Cerebral Ischemia. ( 29896413 )
2018
14
Combined Treatment With Dichloroacetic Acid and Pyruvate Reduces Hippocampal Neuronal Death After Transient Cerebral Ischemia. ( 29593636 )
2018
15
Protective effects of D-Limonene against transient cerebral ischemia in stroke-prone spontaneously hypertensive rats. ( 29399074 )
2018
16
Tumor necrosis factor receptor 2 is required for ischemic preconditioning-mediated neuroprotection in the hippocampus following a subsequent longer transient cerebral ischemia. ( 29777731 )
2018
17
Treatment with Uric Acid Reduces Infarct and Improves Neurologic Function in Female Mice After Transient Cerebral Ischemia. ( 29398531 )
2018
18
Ulinastatin alleviates neurological deficiencies evoked by transient cerebral ischemia via improving autophagy, Nrf-2-ARE and apoptosis signals in hippocampus. ( 29750875 )
2018
19
Long-term treadmill exercise improves memory impairment through restoration of decreased synaptic adhesion molecule 1/2/3 induced by transient cerebral ischemia in the aged gerbil hippocampus. ( 29341891 )
2018
20
Transient cerebral ischemia induces albumin expression in microglia only in the CA1 region of the gerbil hippocampus. ( 28586018 )
2017
21
Cochleovestibular Transient Ischemic Attack as a Manifestation of Patent Foramen Ovale. ( 29360095 )
2017
22
Reduced Severity of Outcome of Recurrent Ipsilateral Transient Cerebral Ischemia Compared with Contralateral Transient Cerebral Ischemia in Rats. ( 28893572 )
2017
23
Metabolomic Estimation of the Diagnosis and Onset Time of Permanent and Transient Cerebral Ischemia. ( 29270918 )
2017
24
Atrial fibrillation detected by external loop recording for seven days or two-day simultaneous Holter recording: A comparison in patients with ischemic stroke or transient ischemic attack. ( 28118928 )
2017
25
Copeptin as a biomarker for prediction of prognosis of acute ischemic stroke and transient ischemic attack: a meta-analysis. ( 27904159 )
2017
26
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). ( 28655834 )
2017
27
CD74-immunoreactive activated M1 microglia are shown late in the gerbil hippocampal CA1 region following transient cerebral ischemia. ( 28487994 )
2017
28
Transient Ischemic Attack in Pediatric Patients With Moyamoya Disease: Clinical Features, Natural History, and Predictors of Stroke. ( 28778481 )
2017
29
Clinical Correlates, Ethnic Differences, and Prognostic Implications of Perivascular Spaces in Transient Ischemic Attack and Ischemic Stroke. ( 28495831 )
2017
30
Prospective testing of ICHD-3 beta diagnostic criteria for migraine with aura and migraine with typical aura in patients with transient ischemic attacks. ( 28372496 )
2017
31
Neuroprotective effect of minocycline on cognitive impairments induced by transient cerebral ischemia/reperfusion through its anti-inflammatory and anti-oxidant properties in male rat. ( 28454931 )
2017
32
Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. ( 29114094 )
2017
33
Fetal Alcohol Exposure Alters Blood Flow and Neurological Responses to Transient Cerebral Ischemia in Adult Mice. ( 27987329 )
2017
34
Neuroprotective effect of safranal, an active ingredient of Crocus sativus , in a rat model of transient cerebral ischemia. ( 28984113 )
2017
35
Vascular and Tissue Changes of Magnetic Susceptibility in the Mouse Brain After Transient Cerebral Ischemia. ( 29177950 )
2017
36
Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With CYP2C19 Genetic Variants. ( 28289237 )
2017
37
Explicit diagnostic criteria for transient ischemic attacks to differentiate it from migraine with aura. ( 28994605 )
2017
38
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. ( 27806998 )
2017
39
Effects of longa89term posta89ischemic treadmill exercise on gliosis in the aged gerbil hippocampus induced by transient cerebral ischemia. ( 28440411 )
2017
40
Dysfunction of Membrane Trafficking Leads to Ischemia-Reperfusion Injury After Transient Cerebral Ischemia. ( 29022237 )
2017
41
Prea89treatment with ChrysanthemumA indicum LinnAc extract protects pyramidal neurons from transient cerebral ischemia via increasing antioxidants in the gerbil hippocampal CA1 region. ( 28534982 )
2017
42
Prolonged Perfusion Predicts Recurrent Ischemic Stroke but not Transient Ischemic Attack in Patients with Symptomatic Intracranial Stenosis. ( 28412909 )
2017
43
Transient Ischemic Attack and Ischemic Stroke in Danon Disease with Formation of Left Ventricular Apical Thrombus despite Normal Systolic Function. ( 29085695 )
2017
44
Puerarin provides a neuroprotection against transient cerebral ischemia by attenuating autophagy at the ischemic penumbra in neurons but not in astrocytes. ( 28192195 )
2017
45
Effects of ischemic preconditioning on PDGF-BB expression in the gerbil hippocampal CA1 region following transient cerebral ischemia. ( 28627606 )
2017
46
Inactivation of NSF ATPase Leads to Cathepsin B Release After Transient Cerebral Ischemia. ( 29039034 )
2017
47
Neuroprotection and reduced gliosis by pre- and post-treatments of hydroquinone in a gerbil model of transient cerebral ischemia. ( 28137511 )
2017
48
Physical Exercise Improves Cognitive Outcomes in 2 Models of Transient Cerebral Ischemia. ( 28663509 )
2017
49
Transient Cerebral Ischemia Alters GSK-3I^ and p-GSK-3I^ Immunoreactivity in Pyramidal Neurons and Induces p-GSK-3I^ Expression in Astrocytes in the Gerbil Hippocampal CA1 Area. ( 28349361 )
2017
50
Effect of patent foramen ovale closure for prevention on recurrent stroke or transient ischemic attack in selected patients with cryptogenic stroke. ( 28833599 )
2017

Variations for Transient Cerebral Ischemia

ClinVar genetic disease variations for Transient Cerebral Ischemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 NOTCH3 NM_000435.2(NOTCH3): c.457C> T (p.Arg153Cys) single nucleotide variant Pathogenic rs797045014 GRCh38 Chromosome 19, 15192182: 15192182
2 NOTCH3 NM_000435.2(NOTCH3): c.457C> T (p.Arg153Cys) single nucleotide variant Pathogenic rs797045014 GRCh37 Chromosome 19, 15302993: 15302993
3 NOTCH3 NM_000435.2(NOTCH3): c.1450T> G (p.Cys484Gly) single nucleotide variant Likely pathogenic GRCh37 Chromosome 19, 15299088: 15299088
4 NOTCH3 NM_000435.2(NOTCH3): c.1450T> G (p.Cys484Gly) single nucleotide variant Likely pathogenic GRCh38 Chromosome 19, 15188277: 15188277

Expression for Transient Cerebral Ischemia

Search GEO for disease gene expression data for Transient Cerebral Ischemia.

Pathways for Transient Cerebral Ischemia

GO Terms for Transient Cerebral Ischemia

Cellular components related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 BAD CASP3 GCKR HSPA1A HSPA4 IL1B
2 NMDA selective glutamate receptor complex GO:0017146 8.62 GRIN2A PTK2B

Biological processes related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.85 CCL2 GRIN2A IL1B PTK2B
2 response to ethanol GO:0045471 9.77 BAD GRIN2A PTK2B
3 response to glucose GO:0009749 9.69 BAD CASP3 PTK2B
4 cellular response to organic cyclic compound GO:0071407 9.65 CASP3 CCL2 IL1B
5 cytokine-mediated signaling pathway GO:0019221 9.65 BAD CASP3 CCL2 IL1B LCN2
6 response to hydrogen peroxide GO:0042542 9.61 BAD CASP3 PTK2B
7 chaperone-mediated protein complex assembly GO:0051131 9.58 HSPA1A HSPA4
8 long term synaptic depression GO:0060292 9.58 DRD1 PTK2B
9 dopamine metabolic process GO:0042417 9.57 DRD1 GRIN2A
10 NAD biosynthetic process GO:0009435 9.56 KMO KYNU
11 response to drug GO:0042493 9.55 BAD CASP3 DRD1 GRIN2A PTK2B
12 activation of cysteine-type endopeptidase activity GO:0097202 9.54 BAD GRIN2A
13 long-term synaptic potentiation GO:0060291 9.54 DRD1 GRIN2A PTK2B
14 pyridine nucleotide biosynthetic process GO:0019363 9.52 KMO KYNU
15 cellular response to organic substance GO:0071310 9.5 CASP3 IL1B MAP2
16 tryptophan catabolic process GO:0006569 9.49 KMO KYNU
17 tryptophan catabolic process to kynurenine GO:0019441 9.46 KMO KYNU
18 positive regulation of glucokinase activity GO:0033133 9.4 BAD GCKR
19 quinolinate biosynthetic process GO:0019805 8.96 KMO KYNU
20 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 8.8 BAD CASP3 IL1B

Molecular functions related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase activator activity involved in apoptotic process GO:0008656 8.96 BAD CASP3
2 NMDA glutamate receptor activity GO:0004972 8.62 GRIN2A PTK2B

Sources for Transient Cerebral Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....